Sidley recently represented Beijing Capital Agribusiness Co., Ltd. (BCA) as it enters into a set of strategic collaboration agreements with Genus plc. in the field of porcine genetics. Under the transaction, BCA has been exclusively licensed by Genus to develop, register, launch and promote pigs resistant to Porcine Reproductive and Respiratory Syndrome virus (PRRSv) in China. This project is expected to require a total investment of US$50-80 million in the next several years, for introducing and developing Genus’ patented technologies and elite porcine germplasm. Following the Chinese regulatory approvals, Genus’ existing porcine genetics operations in China (PIC China) will be combined with the new PRRSv-resistant pig operations wholly owned by BCA; as a result, a joint venture will be created which will be 51% owned by BCA and 49% owned by Genus.
BCA, China’s leading safe food and agribusiness company, has the largest multi-species animal breeding business in China, and Genus (Code: LSE:GNS, a member of the UK Financial Times 250 Index) is a leading global animal genetics company.
Sidley is acting as the transaction counsel as well as U.S. and China regulatory counsel for BCA. The Sidley team is led by senior counsel Chen Yang (Hong Kong/Sydney), supported by associate Mulai Xu (Beijing) and members of the U.S. FDA regulatory group, including partners Diane McEnroe (New York) and Deepti Kulkarni (Washington, D.C.) and counsel Emily Marden (Palo Alto).